Because of its enhanced activation of plasminogen in association with fibrin compared with free plasminogen, tissue-type plasminogen activat or (t-PA) evoked excitement as a potentially useful pharmacologic activator of the fibrinolytic system. Initial studies in experimental animals and patients demonstrated that it induced coronary thrombolysis rapidly and without concomitant, mark ed fibrinogenolysis in contrast tostreptokinase. Large scale clinical trials soon followed. Their results indicate that intravenous admini stration of topA produced hy Fibrinolysis has bee n recognized for more than 200 years , Perhaps surprisingly , coronary throm bolysis has a relative ly long histor y as well , Th e current intense interest in this mode of treatm ent of acute myocardial infarc tion reflects. in part. improved end points of efficacy (co ronary angiogra ms that ca n be acq uired safe ly in critically ill pat ients), increased appreciation of the seminal roles of thrombo sis in the etio logy of transmural myocardial infarction and reperfusio n in the salvage of jeopardized tissue and the availability of activators of the fibrinolytic syste m with relative clot selectivity such as tissue-type plasm inogen activator (tPAl only recently synthesized successfully in pharmaceutical quantities by reco mbinant DNA techn ology (rt-PA ).
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Because of the relati ve clo t selectivity oft-PA , a property reflecting its higher affinity for plasminoge n in the fibrin domai n than for circulating , free plasm inogen , we evaluated human t-PA and subseque ntly rt-P A in ex perimen tal an imals and patients with coro nary thrombosi s (1-5) . Clot lysis was elicited promptl y without marked fibrinoge nopenia or induction of a sys temic lytic state pred isposing to bleedin g, Subseq uently. seve ral large sca le clinica l trials wer e undertake n with rl-PA (6-10). Some of their result s are the subjec t of this brief status repo rt. Because this mate rial addre sses not only publ ished results but also work in prog-recombinant DNA technology (rt-Pa ) elicits coronary thromboly sis in two-thirds or more of treated patients with angiographically documented thrombotic occlusions generally without perturhing hemostatic mechanisms or inducing marked fibrinogenolysis. Bleeding is usually confined to vascular access sites and episodes of major bleeding are rare. Overall 6 week sur vival for treated patients with documented acute myocardial infarction may be as high as 95%. ress, some of the dat a are cited as personal communications provided by inves tigators before completion of manu script s already being prepared , including mater ial co mpiled by Drs. Chesebro , Grossbard , Mueller and Passa mani.
The TIMl Trials Phase I. The Thrombolysis in Myocardial Infarcti on (TIM!) trial conducted by the National Heart, Lung, and Blood Institute (NHLBI) ha s evo lved through several pha ses to date. One (Phase I) docum en ted an almos t twofold gre ater incidence (62 compared with 3 1% ) of angiographically confinne d coro nary thromb oly sis with rt-PA co mpared with streptok inase in a double-blind , prospect ive . rand om se lection desig n ( Fig. I) ( I I) . Sign ificant but modest improvement of global and regional ventric ular function has been evide nt in TIMI trial patients in who m reper fusion was induced by rl-PA within 4 hours of the onset of ches t pa in ( 12.1 3).
Mueller and her colleagues (14) delineated the incidence of bleeding in several phases of the Tl AlI trial to date (FiX. 2) . The incidence of bleeding with strepto kinas e and rt-PA, the two activators used in Phase I, was similar. For rt-PA in all the phases of the T IMI tria l ana lyzed by Mueller et a!. bleedi ng was confined largely to vasc ular access site s (Fig. 3) . Bleed ing with rt-PA was generally but only loosely related to the magnitude of decreased fibrinogen and increase d fibrinogen degr adation products. Nevertheless , the associations support the view that laboratory criteria of a however, based in part on data from several studies and with information obtained from computer-assisted analysis of pharmacodynamics (17) , that consumption of alpha-. antiplasmin indicative of risk occurs with doses and durations of infusion of rt-PA exceeding theoretically defined limits. Accordingly, the TIMI investigators and the TIMI policy board monitored each upen label phase of the trial systemic lytic state portend an increased risk of bleeding, Accordingly, the systemic lytic state seen invariably with even subtherapeutic doses uf conventional activators is not likely to be entirely benign.
Compared with streptokinase, rt-PA lowers plasma fibrinogen markedly less judging from results in subsets of patients with extensive laboratory data analyzed in detail in both TIMI Phase I (data not shown) and the European Cooperative Trial (Fig. 4) (15) . Major bleeding requiring transfusion occurs less frequently with rt-PA than with streptokinase, judging from results in the European Cooperative Trial (Fig. 5) (10,15) .
Open label phases. Several open label phases of TIMI were undertaken in part to delineate optimal dose and duration of treatment with the originally produced rt-PA and with material available subsequently that comprised a larger fraction of so-called single chain (suspension-culture, nonplasmin split) rt-PA, Despite some fluctuation of incidence, major bleeding occurred within a range of 7 to 25% with dose regimens that varied from 80 mg over 3 hours to 150 mg over 6 hours, Attempts to identify the upper bounds of safe dosage were motivated in part by the higher earlier recanalization rates (42 compared with 13% after 30 minutes) when 90 as opposed to 40 mg of rt-PA was given in the first hour. Furthermore, the higher doses of rt-PA used in TIMI open label phase E compared with those used in Phase I were associated with substantially higher rates of patency early (2 hours) and later ( IR to 4R hours) after the onset of infusion (Fig, 6) (16) . It was well recognized, Figure 1 . TIMl phaseI-efficacy. Patency ratesfor patients treated with recombinant tissue-type plasminogen activator (rt-PA) (80 mg over 3 hours)or streptokinase (SK) (1.5 million U over I hour) in the double-blind, random patient selection, prospective study comprising Phase I of the TIMI trial. The number of subjects in the two groups was 113 and 119, respectively. rt-PA was more effective than streptokinase whether recanalization was defined by angiography 30 (hatched bars) or 90 (solid bars) minutes after the onset of administration of the active thrombolytic agent. Figure 5 . Hemorrha gic events within 4l:\ hours after infusion of recombinant tissue-type plasminogen activator (rl-PA) (0.75 mg/kg over 90 minutes) or streptokinase (SK ) (1 .5 million U over 60 minutes) in patients studied by Verstraete et al. (10) in the European Cooperative Trial. Both the incidence of major bleeding and the overall incidence of bleeding were less among patients treated with fl-PA. were associated with a somewhat greater rate of early patency.
• This decision was reinforced by [he lack of a detectable decrea se of efficac y (reca naliz atio n rate for infarct-related Not done Figure 7 . Mortality and morbidity throughout the hospital course and throuehout a 6 week interval of fol low-up among 31 7 patients treated with recombinant tissue-type plasminogen activator ([(-PA) in open label phase E of the TIMI trial us well as the incidence of recurrent myocardial infarction (MI) or extension of infarction during both intervals. Episodes of intracranial bleeding (lC> were included in the tabulation as deaths. Even with the classification of such bleeding episodes as " mortality," survival throughout the hospital course and throughout a 6 week inrerval of follow-upafter infu sion of rt-PA was unusually high (94'k) for patients with documented acute transmural myocardial infarction.
arteries) with the 100 mg compared with the 150 mg dose of n-PA over 6 hours and the virtual absence of intracranial bleeding in patients treated with the 100 mg dose to date. Among 400 patients treated with 120 to 170 mg of rt-PA over intervals comparable with those employed in TIMI open label E and studied in clinical trials monitored by the Gcnentech Corporation. the incidence of intracranial bleeding within 48 hours of infusion of rt-PA was < 0.5%. Among 99R patients treated with equipotent regimens of rt-PA produced by diverse production modes over the past several years it was only 0.3% (19) , Among analogous trials conducted in Europe involving 7H 1 patients it was 0.26% (E.
Grossbard , personal communication).
Th erapeutic failures. When intracranial bleeding and death are considered together a~criteria of failure of therapy with rt-PA, only 5% of 3 17 patients given 150 mg of rt -PA were adjudged to have had therapeutic failure throughout their entire hospitalization in open label phase E of the TIMI trial. Only 6% were adjudged to have had therapeutic failure throughout a 6 week interval 01" follow-up (Fig. 7 ) (E. Passumani. personal communication), Patency occurred in 87lif of 220 patients. judging from results of angiography 18 to 48 hours after treatment. When the dose regimen in open label phase E was modified to 100 mg 01" rt-PA over 6 hours. efficacy remained apparently constant. The incidence of intracranial bleeding at this dose has been low (none among the 53 patients treated with 100 mg in open label phase E).
Assi' lance in the preparation or the typescript hy Lori Dales i.,appreciated.
End point results to date from the two largest prospective. randomized patient assignment. double-blind trials with rt-PA (the TIMI trial and the European Cooperative Trial) are concordant and compatible with those of smaller studies with native t-PA and rt-PA as well as with those of studies of rt-PA combined with angioplasty (20) (21) (22) . In concert. the data indicate that: I) lntruvenou s rt-PA elicits recanalization promptly in > 70% or patients-a success rate comparable with that documented with maximal doses of intracoronary streptokinase: 2) It-PA depletes circulating fi brinogen and elevates circulating fi brinogen degradation products much less than does streptokinase. as reflected by results of prospective, randomized, clinical trials (1 5.23); 3) bleeding associated with administration of rt-PA under research protocol conditions generally involving large doses of heparin concomitantly is confined generally to vascular access sites and is readily manageable; and 4) early treatment with rt-PA is associated with remarkably low hospital and 6 week mortality among patients with documented acute transmural myocardial infarction. 
Conclusions

